Bexarotene
6 NDCs across 6 manufacturers|5 Generic,1 Brand
Bexarotene is used to treat lymphoma, t-cell, cutaneous, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Dec 29, 1999, and the first generic was approved Aug 12, 2014. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $50 million on Bexarotene across 7,109 claims for 1,105 beneficiaries.
Bexarotene is available as 6 NDCs from 6 manufacturers (5 generic, 1 brand), with NADAC prices from $5.60 to $116.45 per EA — the most expensive product costs about 21× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
5G / 1B
Manufacturers
6
competing in market
Price Spread
$5.60 – $116.45
per EA
7d Activity
avg +0.0% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Bausch Health US LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Retinoid class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing BEXAROTENE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TARGRETIN 75 MG CAPSULE | $116.4522 per EA | — |
BEXAROTENE 75 MG CAPSULE | $5.6022 per EA | — |
BEXAROTENE 75 MG CAPSULE | $5.6022 per EA | — |
BEXAROTENE 75 MG CAPSULE | $5.6022 per EA | — |
BEXAROTENE 75 MG CAPSULE | $5.6022 per EA | — |
BEXAROTENE 75 MG CAPSULE | $5.6022 per EA | — |
Frequently Asked Questions
What is Bexarotene used to treat?
Bexarotene is used to treat lymphoma, t-cell, cutaneous, per the National Library of Medicine's MED-RT classification.
When did Bexarotene become available as a generic?
FDA approved the first generic Bexarotene (ANDA) on Aug 12, 2014. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Bexarotene?
In 2024, Medicare Part D spent $50 million on Bexarotene across 7,109 claims for 1,105 beneficiaries.
How many Bexarotene products are on the market?
The Bexarotene drug market contains 6 NDCs from 6 manufacturers — 5 generic and 1 brand product.
What is the price range for Bexarotene?
NADAC reference prices for Bexarotene range from $5.6022 to $116.4522 per EA — the most expensive product costs about 21× the cheapest.
Is generic Bexarotene cheaper than brand?
The average generic NADAC for Bexarotene is $5.6022 per EA, versus $116.4522 for brand-labeled products — brand versions average about 21× the generic price.
Which manufacturers make Bexarotene?
6 manufacturers list Bexarotene in NADAC. Ranked by number of NDCs, the largest are Bausch Health US LLC (1), Upsher-Smith Laboratories LLC (1), ANI Pharmaceuticals, Inc. (1), Amneal Pharmaceuticals NY LLC (1), Mylan Pharmaceuticals Inc. (1).